Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy

• Status: Completed
• Trial end date: 2020-09-03
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial studies fosaprepitant dimeglumine in preventing nausea and vomiting in patients with gastrointestinal cancer receiving combination chemotherapy. Antiemetic drugs, such as fosaprepitant dimeglumine, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Philip Philip
• Collaborator: National Cancer Institute (NCI)
• Treatments: Aprepitant; Fosaprepitant

Criteria

Inclusion Criteria:

• Patient receiving FOLFIRINOX chemotherapy

• Southwest Oncology Group (SWOG) Performance status 0 or 1

• Ability of patient or guardian to understand and to provide voluntary written informed consent

Exclusion Criteria:

• Patient with current illness requiring chronic systemic steroids use or requiring chronic use of anti emetics

• Patients with gastrointestinal (GI) obstruction or active peptic ulcer disease who cannot take oral medication

• Known hypersensitivity to any component of the study regimen

• Patients taking any of the following medications: Oral contraceptives (except for the administration of stopping menses), tolbutamide, phenytoin, midazolam, ketoconazole, rifampin, paroxetine, and Diltiazem

• Pregnant or nursing women

• Patients using illegal drugs